995 related articles for article (PubMed ID: 22474386)
41. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
42. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.
Oweida A; Hararah MK; Phan A; Binder D; Bhatia S; Lennon S; Bukkapatnam S; Van Court B; Uyanga N; Darragh L; Kim HM; Raben D; Tan AC; Heasley L; Clambey E; Nemenoff R; Karam SD
Clin Cancer Res; 2018 Nov; 24(21):5368-5380. PubMed ID: 30042205
[No Abstract] [Full Text] [Related]
43. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.
Huang A; Peng D; Guo H; Ben Y; Zuo X; Wu F; Yang X; Teng F; Li Z; Qian X; Qin FX
Sci Rep; 2017 Feb; 7():42687. PubMed ID: 28202921
[TBL] [Abstract][Full Text] [Related]
44. N-cadherin inhibitor creates a microenvironment that protect TILs from immune checkpoints and Treg cells.
Sun Y; Jing J; Xu H; Xu L; Hu H; Tang C; Liu S; Wei Q; Duan R; Guo J; Yang L
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33692219
[TBL] [Abstract][Full Text] [Related]
45. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
[TBL] [Abstract][Full Text] [Related]
46. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells.
West EE; Jin HT; Rasheed AU; Penaloza-Macmaster P; Ha SJ; Tan WG; Youngblood B; Freeman GJ; Smith KA; Ahmed R
J Clin Invest; 2013 Jun; 123(6):2604-15. PubMed ID: 23676462
[TBL] [Abstract][Full Text] [Related]
47. Th9 cells are subjected to PD-1/PD-L1-mediated inhibition and are capable of promoting CD8 T cell expansion through IL-9R in colorectal cancer.
Wang C; Lu Y; Chen L; Gao T; Yang Q; Zhu C; Chen Y
Int Immunopharmacol; 2020 Jan; 78():106019. PubMed ID: 31776089
[TBL] [Abstract][Full Text] [Related]
48. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
[TBL] [Abstract][Full Text] [Related]
49. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
[TBL] [Abstract][Full Text] [Related]
50. PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors.
Beyrend G; van der Gracht E; Yilmaz A; van Duikeren S; Camps M; Höllt T; Vilanova A; van Unen V; Koning F; de Miranda NFCC; Arens R; Ossendorp F
J Immunother Cancer; 2019 Aug; 7(1):217. PubMed ID: 31412943
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
52. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.
Alvarez M; Simonetta F; Baker J; Morrison AR; Wenokur AS; Pierini A; Berraondo P; Negrin RS
Front Immunol; 2020; 11():7. PubMed ID: 32117218
[TBL] [Abstract][Full Text] [Related]
53. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
54. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells.
Roberts DJ; Franklin NA; Kingeter LM; Yagita H; Tutt AL; Glennie MJ; Bullock TN
J Immunother; 2010 Oct; 33(8):769-79. PubMed ID: 20842060
[TBL] [Abstract][Full Text] [Related]
55. Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model.
Li J; Xu J; Yan X; Jin K; Li W; Zhang R
Med Sci Monit; 2018 Aug; 24():5501-5508. PubMed ID: 30087314
[TBL] [Abstract][Full Text] [Related]
56. Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunological remission of lupus.
Zhang L; Bertucci AM; Ramsey-Goldman R; Burt RK; Datta SK
J Immunol; 2009 Nov; 183(10):6346-58. PubMed ID: 19841178
[TBL] [Abstract][Full Text] [Related]
57. Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors.
Nagato T; Lee YR; Harabuchi Y; Celis E
Clin Cancer Res; 2014 Mar; 20(5):1223-34. PubMed ID: 24389326
[TBL] [Abstract][Full Text] [Related]
58. Dose-dependent effect of anti-CTLA-4 on survival in sepsis.
Inoue S; Bo L; Bian J; Unsinger J; Chang K; Hotchkiss RS
Shock; 2011 Jul; 36(1):38-44. PubMed ID: 21368717
[TBL] [Abstract][Full Text] [Related]
59. CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.
Ren Z; Guo J; Liao J; Luan Y; Liu Z; Sun Z; Liu X; Liang Y; Peng H; Fu YX
Clin Cancer Res; 2017 Jan; 23(1):193-203. PubMed ID: 27354469
[TBL] [Abstract][Full Text] [Related]
60. Donor-antigen Inoculation in the Testis Promotes Skin Allograft Acceptance Induced by Conventional Costimulatory Blockade via Induction of CD8 + CD122+ and CD4 + CD25+ Regulatory T Cells.
Cong L; Wang SF; Zhao ZL; Yang RY
Transplantation; 2016 Apr; 100(4):763-71. PubMed ID: 26569069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]